European Bare Metal Stent Manufacturers Face Stiff

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
European Bare Metal Stent Manufacturers Face Stiff Competition From New Technology

VANCOUVER, BC, Feb. 12, 2015 (GLOBE NEWSWIRE) -- via PRWEB - February 12, 2015 – Vancouver, BC – According to a new report published by iData Research ( http://www.idataresearch.com ), demand for bare-metal stents in Europe could decline dramatically if competing technologies, such as drug-eluting stents and drug-coated balloons provide cost-effective reductions in restenosis. Restenosis is the re-narrowing of treated blood vessel causing obstructions and decreased blood flow to vital organs. The restenosis rate following the use of bare-metal stents remains high, with re-occlusion occurring in up to 50% of cases.

"The European market for bare-metal stents is showing increasing signs of saturation, with intense competition leading to steep ASP declines," explains Dr. Kamran Zamanian, CEO of iData. "This trend has led the major companies in the field to pursue the commercialization of drug-eluting technology, including balloons and stents, which serve as a substitute for bare-metal stents."

Bare metal stents represent the largest peripheral stent segment in Europe, valued at over €166 million. By 2020, the bare metal stent market in Europe will represent slightly above 72% of the total peripheral stent market.

Other key findings from the latest edition of the iData Research report entitled European Markets for Peripheral Vascular Devices :

Clinical Trials
Clinical trials continue to play a central role in proving the efficacy of a particular treatment method and the superiority of a particular product. Recent clinical trials have supported the use of covered and drug-eluting stents. These results, and the release of longer-term data, will continue to drive demand for these products whose efficacy is established.

Price Erosion
Bare metal stents are increasingly perceived as commodities by purchasers. Current generation devices have all shown comparable results in achieving patency. As a result, prices continue to decrease significantly as companies attempt to increase market share. This trend will intensify as lower cost competing devices, such as drug-coated balloons, continue to be used in more procedures.

For Further Information
More on the markets for peripheral vascular devices in Europe can be found in this latest edition report published by iData entitled European Markets for Peripheral Vascular Devices , which covers 15 countries in Europe, as well as 500 market sub-segments by country for peripheral vascular stents, PTA balloon catheters, atherectomy devices, chronic total occlusion devices, embolic protection devices, stent-grafts, surgical grafts, AV access thrombectomy devices, inferior vena cava filters, diagnostic and interventional catheters, standard and hydrophilic guidewires, introducer sheaths, vascular closure devices, and transcatheter embolization devices.

The iData series on the market for peripheral vascular devices also covers the U.S., China, India, Japan, and 15 countries in Europe. Full reports provide a comprehensive analysis including units sold, procedure numbers, market value, forecasts, as well as detailed competitive market shares and analysis of major players' success strategies in each market and segment.

Register online or email us at info(at)idataresearch(dot)net for a European Markets for Peripheral Vascular Devices report brochure and synopsis.

About Procedure Tracker
Procedure number data is available from iData's Procedure Tracker service , which allows subscribers to define and analyze procedure data segmented by state, region, hospital, surgery centre, and physician. A customizable dashboard sorts procedure data for further analysis and research.

About iData Research
iData Research ( http://www.idataresearch.com ) is an international market research and consulting group focused on providing market intelligence for medical device and pharmaceutical companies. iData covers research in: Diabetes Drugs, Diabetes Devices, Pharmaceuticals, Anesthesiology, Wound Management, Orthopedics, Cardiovascular, Ophthalmics, Endoscopy, Gynecology, Urology and more.

This article was originally distributed on PRWeb. For the original version including any supplementary images or video, visit http://www.prweb.com/releases/2015/02/prweb12513593.htm

iData Research Marvin Cidamon +1 (604) 266-6933 Ext: 205

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Weifang's Cultural Resurgence: A Global Epigraphy Fest

Updated Category News Views 44

A Historical Meltdown into Global Recognition Welcome to the ride where ancient stones talk and cultural borders vanish. We're diving into the beating heart of Weifang, a place you're probably hearing about now because the town's hosting a packed international media tour. And, for a change, this isn't just another tourist trap; it's a cultural adrenaline shot to the arm,...

Continue Reading
Masimo's smartSET™ Revolutionizes Patient Monitoring

Updated Category News Views 44

Breaking Ground in Patient Monitoring Let's dive into the gritty details behind Masimo's latest FDA-nod: the smartSET™ system. This gizmo ain't your ordinary pulse oximeter; it's a next-gen hand-holder for the medical world, poised to ride the AI wave straight into the clinic. They've cracked open a new way for clinicians to peek behind the curtain of patient vitals,...

Continue Reading
Innventure Faces Major Lawsuit Over Misleading Investors

Updated Category News Views 61

Missteps at Innventure: A Costly Lesson in Investor Trust The stock market is no stranger to drama, but Innventure's saga feels like a page ripped right out of a thriller novel. You’ve got accusations, alleged fabrications, and a swift drop in stock prices that’s left some investors shaking their heads. The company, nestled under the ticker NASDAQ:INV, finds itself...

Continue Reading
Voter Events by Valley Community Healthcare Aim to Empower

Updated Category News Views 38

Here's a game-changer for the community. Valley Community Healthcare (VCH) is stepping up, proving that healthcare doesn't just stick to check-ups and prescriptions. It's about the whole shebang—community empowerment included. This October, VCH is hosting two incredible voter events, collaborating with the Los Angeles County Registrar-Recorder's Mobile Voting Program....

Continue Reading
Hyliion Class Action Deadline Nears for Investors

Updated Category News Views 56

Potential Shockwaves for Hyliion Investors Investors are having a showdown with Hyliion (NYSE:HYLN) these days. With the looming October 27, 2026, deadline to jump into a securities class action, it seems Hyliion's latest escapade smells worse than a fish market on a hot day. We’ve got allegations here stronger than your uncle’s morning coffee. Understanding the Legal...

Continue Reading
AEVEX Facing Class Action Deadline Amid Stock Turmoil

Updated Category News Views 46

Investors are no strangers to the rough and tumble of stock markets, but things get downright messy when trust is shattered. That's the sorry saga unfolding with AEVEX, where shareholders are feeling the heat after a sharp nosedive in stock value. The clock is ticking to join the class action, and any AEVEX investor worth their salt should pay attention. Unraveling...

Continue Reading
LG OLED evo W6: UAE Roadshow Starts with a Bang

Updated Category News Views 48

They've done it again, folks. LG Electronics is out there kicking up a storm with their all-new OLED evo W6 True Wireless Wallpaper TV, and they're bringing the action straight to the UAE's doorsteps. Imagine taking a stroll and stumbling upon this technological marvel at some fancy spot like The Lotus Lounge at Anantara The Palm Dubai Resort. This ain't just a TV, it's a...

Continue Reading

Top 5 Most Recently Viewed Articles

Cemtrex's Stock Surge Sparks Interest in Leading Movers

Updated Category News Views 117

Cemtrex Experiences Notable Share Surge Shares of Cemtrex, Inc. CETX have seen a significant uptick amid pre-market trading. This boost comes on the heels of better-than-expected sales in the latest quarter, reporting an impressive $18.10 million in sales, surpassing the general analyst expectation of $16.39 million. This remarkable performance in sales has sparked...

Continue Reading
Exciting New PharmD-MBA Pathway Combines Pharmacy and Business

Updated Category News Views 193

Collaboration between Cal Poly Pomona and Western University In an exciting move, Cal Poly Pomona's Singelyn Graduate School of Business and Western University of Health Sciences have teamed up to create a groundbreaking pathway for aspiring healthcare professionals. This innovative PharmD-MBA program combines the fields of pharmacy and business, providing a unique...

Continue Reading
Kaskela Law Investigates Stock Misconduct in Stanley Black & Decker

Updated Category News Views 155

Overview of the Investigation by Kaskela Law LLC Kaskela Law LLC has announced an important investigation focused on Stanley Black & Decker, Inc. (NYSE: SWK) concerning allegations of potential securities fraud. This inquiry is primarily aimed at safeguarding the interests of long-term investors who hold shares in this well-known manufacturing company. Details Surrounding...

Continue Reading
Legend Biotech's Carvykti: A Leading Force in Cancer Treatment

Updated Category News Views 90

Redburn's Positive Outlook for Legend Biotech Recently, Redburn-Atlantic began covering Legend Biotech Corp. (NASDAQ: LEGN) with a favorable Buy rating and set a price target of $86.00 for the stock. This biotechnology company has made significant strides, particularly with the recent approval of its innovative product, Carvykti, designed for the treatment of multiple...

Continue Reading
Transforming the Anti-Obesity Drug Market for Future Success

Updated Category News Views 132

Global Anti-Obesity Drug Market Overview As global health concerns rise, the demand for anti-obesity drugs is surging. Recent reports estimate that the anti-obesity drug market will soar to USD 82.55 billion in the coming years. This impressive growth, fueled by an anticipated compound annual growth rate (CAGR) of 18.01%, signals a crucial moment for pharmaceutical...

Continue Reading